Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
June 19, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit
June 17, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
June 14, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
May 30, 2024 18:05 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
May 14, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
May 13, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024Company to Host Key Opinion Leader Webinar on the Potential of Briquilimab in...
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
May 07, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
March 21, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...